Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
102.87
+0.49 (0.48%)
At close: Apr 2, 2026, 4:00 PM EDT
103.56
+0.69 (0.67%)
After-hours: Apr 2, 2026, 7:53 PM EDT

Abbott Laboratories Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021
Period Ending
Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21 Jun '21 Mar '21
Net Income
1,7761,6441,7791,3259,2291,6461,3021,2251,5941,4361,3751,3181,0331,4352,0182,4471,9892,1001,1891,793
Depreciation & Amortization
792791777756807801805805813824800806807815822823883847874934
Stock-Based Compensation
113120142289111117141304114117132281115123142305106114132288
Change in Receivables
222-202-410-262-158-57-325-15168-461-196233341530-188-751-189-39435165
Changes in Inventories
2342133-255235220-103-410295140-248-419-189-194-476-5541571-5-537
Changes in Other Operating Activities
-221-244-436--22140-748--179-660-1,076-7192-205--37-97-6
Operating Cash Flow
3,3152,7872,0471,4172,8682,7051,9601,0253,0381,8771,2031,1432,3262,7802,4102,0653,0672,7012,1282,637
Operating Cash Flow Growth
15.59%3.03%4.44%38.24%-5.60%44.11%62.93%-10.32%30.61%-32.48%-50.08%-44.65%-24.16%2.93%13.25%-21.69%-19.25%30.74%60.97%268.81%
Capital Expenditures
-689-496-502-484-720-556-533-398-755-560-507-380-610-467-379-321-614-461-413-397
Proceeds from Sale of Investments
-4390-52819-4077-2888-3879-86155-2159-41104-10895-14
Payments for Business Acquisitions
-20-55-15-----0-51-413-----0-1720-15
Proceeds from Business Divestments
----000.5-0020-0024-08624-
Other Investing Activities
6426422121514848212464
Investing Cash Flow
-913-457-582-470-866-594-453-425-824-634-1,213-462-632-484-264-360-671-651-264-422
Long-Term Debt Issued
202111221-100.5-013-40--
Long-Term Debt Repaid
-1-501-1-1,001-640-2-18--1,051-1,445-1-0-1-1-751-3-40-3-2
Net Long-Term Debt Issued (Repaid)
1-5011-1,000-639-1203--1,050-1,445-0.5-002-7511-40-3-2
Issuance of Common Stock
56935287259213134345615624157105982701786
Repurchase of Common Stock
-302-305-6-280-315-751-3-226-259-2-426-540-685-798-5-2,307-974-579-471-275
Net Common Stock Issued (Repurchased)
-297-236297-290-65910-92-22554-411-478-644-7415-2,248-892-509-454-189
Common Dividends Paid
-1,030-1,031-1,029-1,026-958-960-961-957-888-888-890-890-823-826-828-832-798-801-803-800
Other Financing Activities
-718-57-362644-43-127111-6113-42102458-197-27-424
Financing Cash Flow
-1,397-1,760-1,097-2,055-1,861-1,576-791-1,176-2,052-2,340-1,289-1,410-1,457-1,543-813-3,823-1,886-1,377-1,264-967
Effect of Exchange Rate Changes on Cash and Cash Equivalents
6-105124-8336-13-3625-29-27851-96-71-6-13-294-32
Net Cash Flow
1,011560419-1,08458571703-612187-1,126-1,326-7212886571,262-2,1244976446041,216
Free Cash Flow
2,6262,2911,5459332,1482,1491,4276272,2831,3176967631,7162,3132,0311,7442,4532,2401,7152,240
Free Cash Flow Growth
22.25%6.61%8.27%48.80%-5.91%63.17%105.03%-17.82%33.04%-43.06%-65.73%-56.25%-30.04%3.26%18.43%-22.14%-21.35%42.68%152.21%530.99%
FCF Margin
22.92%20.15%13.87%9.01%19.57%20.21%13.75%6.29%22.29%12.98%6.98%7.83%17.01%22.22%18.04%14.66%21.39%20.50%16.78%21.42%
Free Cash Flow Per Share
1.501.310.880.531.231.230.810.361.310.750.400.440.971.311.150.981.381.250.961.25
Levered Free Cash Flow
2,1141,8721,814-948,9122,0881,814474897216759.52491,0411,6602,0791,4392,2742,4801,5451,785
Unlevered Free Cash Flow
2,0322,2801,732842.669,0102,0201,661431.351,9341,640681204.281,0281,6702,0982,2212,3172,5651,5871,845
Updated Jan 22, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q